cagrilintide/semaglutide vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
Reported efficacy
Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)
Result source: NCT05394519
MET-233i
Developed by Pfizer and partners
NCT07022977 · Phase 1 · completed
A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.
Next expected readout: January 2027 · NCT07725809 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | cagrilintide/semaglutide | MET-233i |
|---|---|---|
| Body weight, % change | -13.7% vs -3.4%a−10.3 vs placeboNCT053945191 other result
| —Not reported |
| Weight loss of 5% or more | —Not posted · NCT05996848 | —Not reported |
| Weight loss of 10% or more | —Not posted · NCT05996848 | —Not reported |
| Waist circumference, change (cm) | —Not posted · NCT05996848 | —Not reported |
Body weight, % change
- cagrilintide/semaglutide
- -13.7% vs -3.4%a−10.3 vs placeboNCT05394519
1 other result
- -18.4% vs -11.9% NCT05813925
- MET-233i
- —Not reported
Weight loss of 5% or more
- cagrilintide/semaglutide
- —Not posted · NCT05996848
- MET-233i
- —Not reported
Weight loss of 10% or more
- cagrilintide/semaglutide
- —Not posted · NCT05996848
- MET-233i
- —Not reported
Waist circumference, change (cm)
- cagrilintide/semaglutide
- —Not posted · NCT05996848
- MET-233i
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
MET-233i: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide/semaglutide
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · MET-233i's landscape